Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration

Latest


How Immunotherapy Makes Cancer Disappear Without Surgery
1:10
How Immunotherapy Makes Cancer Disappear Without Surgery
2 hours ago
by
Emily Schoenthaler(+1 more)
Applying Small Molecule Agility to Biologics
0:40
Applying Small Molecule Agility to Biologics
2 days ago
by
Michael Christel(+2 more)
The Future of Antibody Manufacturing
0:39
The Future of Antibody Manufacturing
3 days ago
by
Michael Christel(+2 more)
How FDA is Changing Rare Disease Drug Approvals
1:00
How FDA is Changing Rare Disease Drug Approvals
3 days ago
by
Emily Schoenthaler(+1 more)
FDA Investigates Cancer Risk in Novartis' Gene Therapy
1:07
FDA Investigates Cancer Risk in Novartis' Gene Therapy
7 days ago
by
Emily Schoenthaler
FDA Grants Accelerated Approval for New Cancer Treatment
1:28
FDA Grants Accelerated Approval for New Cancer Treatment
10 days ago
by
Emily Schoenthaler
A Potential Breakthrough for Huntington's Disease
1:56
A Potential Breakthrough for Huntington's Disease
15 days ago
by
Emily Schoenthaler
Why Developability Matters in Drug Manufacturing
0:39
Why Developability Matters in Drug Manufacturing
16 days ago
by
Emily Schoenthaler
AAPS 2026 PharmSci 360: A Video Recap
1:10
AAPS 2026 PharmSci 360: A Video Recap
20 days ago
by
Feliza Mirasol(+2 more)
A Potential Game Changer for At-Home Medical Treatment
1:23
A Potential Game Changer for At-Home Medical Treatment
20 days ago
by
Emily Schoenthaler(+1 more)

Analytics for Bispecific Antibody Product Release

Planning the analytical strategy for product release should be started as early as possible to ensure product quality and regulatory success.

Analytics for Bispecific Antibody Product Release

FAQ: What You Need to Know About Analytical Method Validation

We answer readers’ top questions on limit of blank, limit of detection, limit of quantitation, acceptance criteria, and equivalence testing in analytical method validation.

FAQ: What You Need to Know About Analytical Method Validation

Digital Standards Aim to Modernize Quality Assurance Without Compromising Confidence

As quality control labs move toward more connected, data-driven operations, digital technologies must be adopted in a way that upholds patient safety.

Digital Standards Aim to Modernize Quality Assurance Without Compromising Confidence

What FDA's AI Warning Letter Tells Us About GMP Accountability

An FDA warning letter to Purolea Cosmetics Lab shows that AI-assisted drafting can support documentation work only when the resulting document is subject to quality-system controls.

What FDA's AI Warning Letter Tells Us About GMP Accountability

Expedited Regulatory Pathways for Biologics

This episode of the BioPharm Drug Digest will examine strategic triggers that have thus far won expedited regulatory review for biologics in development.

Expedited Regulatory Pathways for Biologics


All News

Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com

The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.

FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.